filmov
tv
Moderna Vaccine Had Decade Head Start Over Pfizer: Chairman
Показать описание
Nov.16 -- Moderna Inc. reported its Covid-19 vaccine was 94.5% effective in a preliminary analysis of a large late-stage clinical trial. Noubar Afeyan, Moderna co-founder and chairman, discusses the company's new data, distribution, plan for emergency use authorization and its advantage over a vaccine by Pfizer Inc. Afeyan spoke with Bloomberg's Emily Chang.
Moderna Vaccine Had Decade Head Start Over Pfizer: Chairman
The President of Moderna Gives a Crash Course on COVID-19 Vaccines
Moderna COVID Vaccine Heads into Larger Study
Dr. Gottlieb on Moderna vaccine: We can effectively end Covid-19 pandemic in 2021
What we know about Moderna's COVID-19 vaccine candidate -- and what we don't
Stroke and death after Moderna
Matt Hancock: UK has secured 5 million doses of Moderna's Covid vaccine
Does Moderna’s COVID-19 vaccine have an advantage over Pfizer’s?
Moderna Has Chance to Be ‘Vaccine of Choice’: Johns Hopkins
Moderna: Vaccine Protection Lasts a Year
Moderna says COVID vaccine effective in 6 to 11-year-olds
The race for a Covid-19 vaccine with Moderna, Pfizer and BioNTech | WIRED Health:Tech 2020
How Moderna And Pfizer-BioNTech Developed Vaccines In Record Time
Moderna COVID-19 vaccine 94.5% effective, company says
168,000 Moderna COVID-19 vaccines could be in Canada by year's end
COVID-19: Moderna vaccine boss 'very confident' on effectiveness
Matt Hancock: Britain has ordered 5 million Moderna vaccines
Moderna Vaccine Distribution Begins
Moderna COVID-19 Vaccine Appears Just As Effective As Pfizer's, Local Doctor Says
Moderna vaccine would add flexibility to Ontario vaccine rollout, says head of task force
U.S. drugmaker Moderna says vaccine 94.5% effective
Coronavirus vaccine potentially ready by year's end as Moderna seeks EUA approval
Moderna says vaccine is 94.5 percent effective
Moderna’s Co-Founder on the Sprint for a Covid-19 Vaccine
Комментарии